Nicox SA says it “has risen from the ashes” over the past several years to reposition itself as a specialist in ophthalmology through four separate acquisitions, and is now building commercial teams in Europe’s five top markets to attract U.S. partners seeking entries into the region’s eye-care sector.
The small France-based biotech has been pursuing that focused strategy since suffering a major setback four years ago, when its lead compound at the time was rejected by U.S. and European regulators
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?